Singapore
Allozymes, founded in 2020 and headquartered in Singapore, is positioned at the cutting edge of the biotechnology industry with a focus on B2B, Biotechnology, and Health Care. Known for its slogan, "Evolving Biology, Advancing Tomorrow," the company leverages an innovative mix of biocatalysis, enzyme discovery, and microfluidic technology to streamline enzyme engineering. Its proprietary ultra-high-throughput microfluidic and AI-driven screening platform is critical in facilitating the rapid development of customized enzymes that serve sectors like biomanufacturing, pharmaceuticals, and life sciences.
In its quest to construct the world's most comprehensive enzyme data library, Allozymes is rapidly advancing toward enabling accelerated discovery, improved optimization, and sustainable production across various industries. This has attracted significant investor interest, leading to a recent $15.00M Series A investment concluded on 01 May 2024. Key investors include SOSV, Entrepreneur First, ID Capital, Seventure Partners, Thia Ventures, Xora Innovation, Transpose Platform, and NUS Technology Holdings.
